The SfN 2023 Annual Meeting ran from November 11 to 15, 2023, in Washington, USA, and drew neuroscience groups from academic laboratories, hospitals, and industry. For a preclinical group working on CNS disease, the meeting is one of the few places where model developers, imaging specialists, and program teams meet in the same hall.
Prisys Biotech presented its nonhuman primate (NHP) disease model platforms and supporting services at the meeting. Four areas were highlighted:
- Quantitative analysis system of NHP behavior: Prisys Biotech can assess the cognitive and motor functions of NHPs by using markerless 3D behavioral motion capture, markerless posture evaluation, deep learning and 3D skeleton reconstruction. Because no markers are attached to the animal, sessions can be recorded repeatedly without extra handling stress, and the resulting tracks are scored the same way across observers. This work sits within the AI-based NHP Behavior Analysis System used for behavioral readouts in NHP studies.
- Novel NHP Model for Neurodegenerative Diseases: Prisys Biotech has developed new NHP models of neurodegenerative diseases such as pain, Parkinson's disease, Alzheimer's disease, depression, MCAO and amyotrophic lateral sclerosis (ALS), which have high pathological and clinical relevance. These models provide a platform for mechanism study and drug development in neurodegenerative disease.
- Advanced Clinical Imaging Capability: Prisys Biotech integrates several imaging systems, encompassing a clinical-level aseptic surgical operating room (OR), mixed surgical devices with digital subtraction angiography (DSA), and imaging equipment (CT, MR, Doppler ultrasound). The angiography work runs on a DSA-Guided Interventional Platform. This combination supports standard and advanced sequence analysis of central nervous system (CNS)-related images, so anatomical and vascular information can be reviewed within the same study.
- Brain-Specific Drug Delivery and Sampling System Under Precise Magnetic Resonance: Prisys Biotech's real-time magnetic resonance-compatible system facilitates precise drug delivery in the brain, minimally invasive sampling of brain tissue, and accurate placement of brain electrodes guided by magnetic resonance, an approach that belongs to the company's MRI-Guided Drug Delivery For CNS Research platform. The same workflow underpins targeting work in neuroscience studies.
Prisys Biotech offers a spectrum of services, including pharmacological efficacy research, pharmacokinetics, safety evaluation, biomarker research, and mechanism concept verification based on the nonhuman primate (NHP) disease model. Much of this work is organized around NHP Pharmacology rather than single assays, which lets efficacy, exposure, and safety readouts come from the same animal where a study design allows. Recognized as a national "high-tech enterprise" and a "specialized and innovative small and medium-sized enterprise in Shanghai," Prisys Biotech remains committed to advancing delivery, evaluation, and model innovation in the CNS field, and welcomes discussions with groups planning NHP-based programs.
